OncoResponse, a Houston, TX-based immuno-oncology antibody discovery company, received an investment from Baxalta Incorporated (NYSE: BXLT) and closed its $12.5m Series A funding.
In October 2015, OncoResponse closed a Series A financing co-led by ARCH Venture Partners, Canaan Partners and MD Anderson, with participation from William Marsh Rice University and Alexandria Real Estate Equities.
The funds will be used to support the company’s ongoing efforts to interrogate the humoral response of elite responders to cancer immunotherapy to identify antibodies and potential targets for novel therapeutic development.
Led by Clifford J. Stocks, CEO, OncoResponse utilizes a validated platform technology to screen antibodies made by the human immune system and identify those with exceptional reactivity to cancer immunotherapy. The company has an ongoing strategic alliance with the MD Anderson Cancer Center, which provides access to patient samples and oncology and translational medicine expertise including clinical and regulatory input.